- Home
- LOBO vs BCTX Comparison
LOBO vs BCTX Comparison
Compare LOBO & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOBO
- BCTX
- Stock Information
- Founded
- LOBO 2014
- BCTX 2014
- Country
- LOBO China
- BCTX Canada
- Employees
- LOBO N/A
- BCTX N/A
- Industry
- LOBO
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- LOBO
- BCTX Health Care
- Exchange
- LOBO NYSE
- BCTX Nasdaq
- Market Cap
- LOBO 19.9M
- BCTX 17.2M
- IPO Year
- LOBO 2024
- BCTX N/A
- Fundamental
- Price
- LOBO $2.15
- BCTX $0.60
- Analyst Decision
- LOBO
- BCTX Strong Buy
- Analyst Count
- LOBO 0
- BCTX 1
- Target Price
- LOBO N/A
- BCTX $15.00
- AVG Volume (30 Days)
- LOBO 27.1K
- BCTX 948.2K
- Earning Date
- LOBO 11-25-2024
- BCTX 12-12-2024
- Dividend Yield
- LOBO N/A
- BCTX N/A
- EPS Growth
- LOBO N/A
- BCTX N/A
- EPS
- LOBO 0.00
- BCTX N/A
- Revenue
- LOBO $19,469,766.00
- BCTX N/A
- Revenue This Year
- LOBO $72.16
- BCTX N/A
- Revenue Next Year
- LOBO $41.04
- BCTX N/A
- P/E Ratio
- LOBO $1,805.80
- BCTX N/A
- Revenue Growth
- LOBO N/A
- BCTX N/A
- 52 Week Low
- LOBO $1.35
- BCTX $0.46
- 52 Week High
- LOBO $4.70
- BCTX $5.97
- Technical
- Relative Strength Index (RSI)
- LOBO N/A
- BCTX 33.57
- Support Level
- LOBO N/A
- BCTX $0.57
- Resistance Level
- LOBO N/A
- BCTX $0.74
- Average True Range (ATR)
- LOBO 0.00
- BCTX 0.06
- MACD
- LOBO 0.00
- BCTX -0.02
- Stochastic Oscillator
- LOBO 0.00
- BCTX 7.58
About LOBO LOBO EV TECHNOLOGIES LTD
Lobo EV Technologies Ltd is an electric vehicle manufacturer and seller company. It designs, develops, manufactures, and sells e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles such as golf carts and mobility scooters for the elderly and disabled persons, also provides automobile information and entertainment software development and design services to customers. The company operates in two operating segments: Electric vehicles and accessories sales which generates key revenue, and software royalties and development and design services. It generates all of its revenue within the People's Republic of China.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.